GAMMA Investing LLC Has $1.30 Million Position in Dynavax Technologies Corporation (NASDAQ:DVAX)

GAMMA Investing LLC lifted its stake in Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) by 2,343.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 100,245 shares of the biopharmaceutical company's stock after buying an additional 96,143 shares during the period. GAMMA Investing LLC owned approximately 0.08% of Dynavax Technologies worth $1,300,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in the stock. Palumbo Wealth Management LLC acquired a new position in shares of Dynavax Technologies in the 4th quarter valued at approximately $275,000. Schonfeld Strategic Advisors LLC increased its stake in Dynavax Technologies by 97.6% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 310,430 shares of the biopharmaceutical company's stock valued at $3,964,000 after acquiring an additional 153,302 shares during the last quarter. First Trust Advisors LP acquired a new position in Dynavax Technologies during the fourth quarter valued at approximately $847,000. Deep Track Capital LP lifted its stake in Dynavax Technologies by 42.0% during the fourth quarter. Deep Track Capital LP now owns 17,791,486 shares of the biopharmaceutical company's stock worth $227,197,000 after purchasing an additional 5,265,000 shares during the last quarter. Finally, Deutsche Bank AG lifted its stake in Dynavax Technologies by 49.3% during the fourth quarter. Deutsche Bank AG now owns 126,398 shares of the biopharmaceutical company's stock worth $1,614,000 after purchasing an additional 41,720 shares during the last quarter. 96.96% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on DVAX shares. William Blair reiterated an "outperform" rating on shares of Dynavax Technologies in a research note on Friday, February 21st. HC Wainwright reaffirmed a "buy" rating and issued a $31.00 price objective on shares of Dynavax Technologies in a research note on Friday, February 21st. Wall Street Zen downgraded Dynavax Technologies from a "buy" rating to a "hold" rating in a research note on Tuesday, May 6th. The Goldman Sachs Group dropped their target price on shares of Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating for the company in a report on Thursday, April 17th. Finally, JMP Securities decreased their price target on shares of Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating on the stock in a report on Wednesday, May 7th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $24.00.

Dynavax Technologies Price Performance

DVAX stock traded up $0.31 during midday trading on Thursday, reaching $10.30. 3,059,180 shares of the stock were exchanged, compared to its average volume of 2,203,802. Dynavax Technologies Corporation has a 52 week low of $9.22 and a 52 week high of $14.63. The company has a fifty day moving average price of $10.34 and a 200 day moving average price of $12.11. The company has a debt-to-equity ratio of 0.49, a current ratio of 11.93 and a quick ratio of 10.84. The stock has a market capitalization of $1.24 billion, a PE ratio of -19.81 and a beta of 1.06.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.14). The firm had revenue of $68.16 million for the quarter, compared to the consensus estimate of $70.01 million. Dynavax Technologies had a positive return on equity of 3.59% and a negative net margin of 20.39%. As a group, analysts expect that Dynavax Technologies Corporation will post 0.32 EPS for the current fiscal year.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.